These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 187150)
1. Comparison of the humoral and cellular immune response after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations. Cappel R Arch Virol; 1976; 52(1-2):29-35. PubMed ID: 187150 [TBL] [Abstract][Full Text] [Related]
2. Humoral and cellular immune responses to an envelope-associated antigen of herpes simplex virus. Zaia JA; Palmer EL; Feorino PM J Infect Dis; 1975 Dec; 132(6):660-6. PubMed ID: 172562 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of a nucleic acid free herpetic subunit vaccine. Cappel R; de Cuyper F; Rickaert F Arch Virol; 1980; 65(1):15-23. PubMed ID: 6252864 [TBL] [Abstract][Full Text] [Related]
4. In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus. Rosenberg GL; Farber PA; Notkins AL Proc Natl Acad Sci U S A; 1972 Mar; 69(3):756-60. PubMed ID: 4335071 [TBL] [Abstract][Full Text] [Related]
6. Lymphocyte stimulation by herpes simplex virus (HSV) antigens. 1. Culture conditions, cell fractionation and presentation of HSV antigens. Kapoor AK; Ling NR; Bazeley M Cytobios; 1977; 20(79-80):151-62. PubMed ID: 216529 [TBL] [Abstract][Full Text] [Related]
7. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection. Chan WL; Lukig ML; Liew FY J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536 [TBL] [Abstract][Full Text] [Related]
8. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. Kumaraguru U; Gierynska M; Norman S; Bruce BD; Rouse BT J Virol; 2002 Jan; 76(1):136-41. PubMed ID: 11739679 [TBL] [Abstract][Full Text] [Related]
9. [Herpes simplex virus vaccine studies: from past to present]. Us D Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine. Irie H; Harada Y; Kataoka M; Nagamuta M; Moriya Y; Handa M; Saito M; Matsubara S; Kojima K; Sugawara Y J Virol; 1992 Apr; 66(4):2428-34. PubMed ID: 1312638 [TBL] [Abstract][Full Text] [Related]
17. Experimental ulcerative herpetic keratitis. IV. Preliminary observations on the efficacy of a herpes simplex subunit vaccine. Carter CA; Hartley CE; Skinner GR; Turner SP; Easty DL Br J Ophthalmol; 1981 Oct; 65(10):679-82. PubMed ID: 6274376 [TBL] [Abstract][Full Text] [Related]
18. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes. Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102 [TBL] [Abstract][Full Text] [Related]
19. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533 [TBL] [Abstract][Full Text] [Related]
20. Effects of in vivo depletion of immunocyte populations on herpes simplex virus glycoprotein D vaccine-induced resistance to HSV2 challenge. Mishkin EM; Blasiak M; Giorgio D; Ishizaka ST Viral Immunol; 1992; 5(2):151-61. PubMed ID: 1319710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]